Exploring the anti-cancer potential of SGLT2 inhibitors in breast cancer treatment in pre-clinical and clinical studies

The link between type 2 diabetes mellitus (T2DM) and an increased risk of breast cancer (BC) has prompted the exploration of novel therapeutic strategies targeting shared metabolic pathways. This review focuses on the emerging evidence surrounding the potential anti-cancer effects of sodium-glucose...

Full description

Saved in:

Bibliographic Details
Published in:	European journal of pharmacology Vol. 978; p. 176803
Main Authors:	Naeimzadeh, Yasaman, Tajbakhsh, Amir, Nemati, Mahnaz, Fallahi, Jafar
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier B.V 05.09.2024
Subjects:	Animals Antineoplastic agents Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Breast neoplasms Breast Neoplasms - drug therapy Clinical Trials as Topic Diabetes mellitus Female Gene mutations Humans Precision medicine SGLT2 inhibitor Sodium-Glucose Transporter 2 Inhibitors - pharmacology Sodium-Glucose Transporter 2 Inhibitors - therapeutic use Breast neoplasms Gene mutations Precision medicine Antineoplastic agents SGLT2 inhibitor Diabetes mellitus
ISSN:	0014-2999, 1879-0712, 1879-0712
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!